Praveen Kammar: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?
Praveen Kammar/LinkedIn

Praveen Kammar: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?

Praveen Kammar, Director at Specialty Surgical Oncology Hospital and Research Center, shared on LinkedIn:

“PERISCOPE II: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?

The recently published PERISCOPE II trial adds important randomized evidence to this ongoing debate.

In 102 patients with limited peritoneal metastases (PCI <7) and/or positive peritoneal cytology, gastrectomy + CRS-HIPEC failed to demonstrate an overall survival benefit over continued systemic therapy.

Key findings:

  • Median OS: 15.7 vs 16.6 months (HR 1.10; p=0.70)
  • Grade ≥3 adverse events: 42% vs 20%
  • Three treatment-related deaths in the experimental arm.

However, the trial raises important questions.

It was stopped prematurely, patient numbers were small, treatment crossover occurred, and a substantial proportion of patients assigned to CRS-HIPEC never underwent the procedure.

The per-protocol analysis numerically favoured CRS-HIPEC (HR 0.66; p=0.12), although this remains hypothesis-generating.

My takeaway: PERISCOPE II does not support routine CRS-HIPEC in this setting. But the results have to be interpreted qith caution.

What are your thoughts?”

Praveen Kammar: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?

You can also read: PERISCOPE II: Gastrectomy, Cytoreductive Surgery, and HIPEC Do Not Improve Survival in Gastric Cancer With Limited Peritoneal Metastases

Praveen Kammar: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?